# Compass Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/compass-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.compasstherapeutics.com
- Total disclosed funding: $49M
- Latest round: Series A (Jul 11, 2018)
- Investors on record: 11

## About

Founded in 2014 by CEO Thomas Schuetz and CSO Piotr Bobrowicz and based in Massachusetts, US, Compass Therapeutics, Inc. is a biotechnology company that focuses on the development of therapeutic antibodies for the treatment of cancer and other tumor-immune synapses. In June 2020, Compass Therapeutics LLC raised USD 60 million in PIPE funding from Consonance Capital Partners and Limulus Venture Partners. Biomatics Capital Partners, BioMed Ventures, Borealis Ventures, and other investors also participated in the round. In June 2020, after the merger with Olivia Ventures, Inc., Compass Therapeutics, Inc. will operate as a public company. In November 2021, Compass Therapeutics, Inc. raised USD 125 million in a private placement, selling 35.72 million shares at USD 3.50 per share on the NASDAQ. It trades on NASDAQ under the ticker symbol CMPX. In May 2021, Compass Therapeutics, Inc. acquired TRIGR Therapeutics, Inc.,  a private biotechnology oncology company, in a stock for stock transaction. 

The products in the company's pipeline include CTX-009, CTX-471, CTX-8371. CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). CTX-009 has completed Phase 1 dose-escalation and expansion study, and a Phase 1b in combination with chemotherapy is ongoing. CTX-009 has shown clinical efficacy as a monotherapy in severely pre-treated patients who have progressed following prior VEGF, EGFR, HER2, and PD1/L1-targeted treatments. CTX-471 is a fully human agonistic antibody of CD137. CTX-471 is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. CTX-8371 is a bispecific antibody that targets both the programmed death receptor (PD-1) and the programmed death ligand-receptor (PD-L1) on immune and cancer cells, respectively. CTX-8371 is currently undergoing IND-enabling preclinical development.  

Compass Therapeutics, Inc. plans to use the PIPE funding for the advancement of its antibody-based therapeutics into clinics.

## Funding rounds

- Series A, Jul 11, 2018, $49M — OrbiMed Advisors, Healthcare Royalty Partners, Alexandria Venture Investments, Borealis Ventures, F-Prime Capital, Valar, BioMed Ventures, Biomatics Capital Partners, Ulysses Holdings
- Series A, Jun 30, 2015 — F-Prime Capital, Borealis, Alumni Ventures Group

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Borealis — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series A
- Valar (https://capitalatlas.ai/funds/valar) — Series A
- BioMed Ventures — Series A
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series A
- Ulysses Holdings (https://capitalatlas.ai/funds/ulysses-holdings) — Series A